Starlight Cardiovascular, Inc.
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $7.9M has been obligated and $5.2M paid out. $2.7M has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$2.2M3
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
STARLIGHT CARDIOVASCULAR, INC. — Grant R44HL162218
DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME - ABSTRACT STARLIGHT CARDIOVASCULAR IS DEVELOPING WHAT WILL BE THE FIRST FDA APPROVED PERCUTANEOUS FLOW RESTRICTOR TO REPLACE SURGICAL BANDING IN CONGENITAL HEART DISEASE (CHD). MANY BABIES WITH CHDS SUCH AS HYPOPLASTIC LEFT HEART SYNDROME AND COMMUNICATING HEART DEFECTS HAVE OVERCIRCULATION TO THE LOWER-RESISTANCE PULMONARY BED AND UNDERCIRCULATION TO THE REST OF THE BODY. REDUCING PULMONARY ARTERY FLOW IN THESE BABIES CREATES A MORE PHYSIOLOGIC BALANCE BETWEEN PULMONARY AND SYSTEMIC CIRCULATIONS AND ALLOWS THEM TO SURVIVE THE FIRST FEW WEEKS OF LIFE, REDUCES DAMAGE TO THEIR PULMONARY ARTERIES, AND ENABLES THEM TO GROW LARGER AND STRONGER PRIOR TO THEIR NEXT, MORE INVASIVE SURGERY TO REPAIR THEIR HEART DEFECT. CURRENTLY, THE REDUCTION OF PULMONARY BLOOD FLOW IN THESE NEONATAL PATIENTS IS ACHIEVED BY SURGICAL PULMONARY ARTERY BANDING, BUT BANDING REQUIRES AN OPEN-CHEST SURGERY AND CAN INTERFERE WITH PULMONAR
Timeline
No timeline articles for this company yet.